



FORM PTO-1449 (modified)
(PW FORM PAT-1449)

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: April 6, 2004

Page 1 of 4

Atty. Ref. No.
037003-0277847

Client Ref. No.
1998-30-0523VUS

Applicant: GRILLO-LOPEZ

Appn. No.: 09/762,587

Filing Date: September 6, 2001

Examiner: M.T.B. Davis | Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)			
YU	AR	4,831,175	05/1989	Gansow			
	BR	5,099,069	03/1992	Gansow			
	CR	5,124,471	06/1992	Gansow			
	DR	5,246,692	09/1993	Gansow			
	ER	5,286,850	02/1994	Gansow			
	FR	5,460,785	10/1995	Rhodes			
	GR	5,500,362	03/1996	Robinson			
	HR	5,677,180	10/1997	Robinson			
	IR	5,721,108	02/1998	Robinson			
	JR	5,843,398	12/1998	Kaminski			
	KR	5,843,439	12/1998	Anderson			
	LR	6,015,542	01/2000	Kaminski			
	MR	6,090,365	07/2000	Kaminski			
	NR	6,120,767	09/2000	Kaminski			
	OR	6,287,537	09/2001	Robinson			
	PR	6,399,061	06/2002	Anderson			
	QR	6,455,043	09/2002	Grillo-Lopez			
	RR	6,565,827	05/2003	Kaminski			
	SR	6,652,852	11/2003	Robinson			

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
YU	TR	WO87/02671A1	05/1987	PCT	Robinson		
	UR	WO88/04936A1	07/1988	PCT	Robinson		
↓	VR	WO89/00999A1	02/1989	PCT	Robinson		

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

YU	WR	Anderson, K.C. et al. "Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow," <i>Blood</i> , 1987, 69(2):597-604.
	XR	Azogui, O. et al., "Inhibition of IL 2 production after human allogeneic bone marrow transplantation," <i>J Immunol</i> , 1983, 131:1205-1208.
	YR	Berinstein, N.L. et al., "Association of serum Rituximab (IDE-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma," <i>Annals of Oncology</i> , 1998, 9(9):995-1001.
↓	ZR	Bosly, A., et al., "Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease," <i>Nouv Rev Fr Hematol</i> , 1990, 32(1):13-16.



	AAR	Byrd, J.C. et al., "Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid tumor lysis," <i>Blood</i> , 1998, 92(10):106a, abstract #432.
	BBR	Byrd, J.C. et al., "Rituximab therapy in previously treated Waldenstrom's Macroglobulinemia: Preliminary evidence of activity." <i>Blood</i> , 1998, 92(10):106(a), abstract #433.
	CCR	Caligiuri, M.A. et al., "Extended continuous infusion low-dose recombinant Interleukin-2 in advanced cancer. Prolonged immunomodulation without significant toxicity." <i>J Clin Oncol</i> , 1991, 9(12):2110-2119.
	DDR	Caligiuri, M.A. et al., "Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant Interleukin 2," <i>J Clin Invest</i> , 1993, 91(1):123-132.
	EER	Caligiuri, M.A., "Low-dose recombinant Interleukin-2 therapy: rationale and potential clinical applications," <i>Semin Oncol</i> , 1993, 20(6 suppl 9):3-10.
	FFR	Cayeux, S. et al., "T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize Interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4+ and CD8+ cells even in the presence of exogenous IL-2," <i>Blood</i> , 1989, 74(6):2270-2277.
	GGR	Czuczman, M.S. et al., "Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy," <i>Journal of Clinical Oncology</i> , 1999, 17(1):268-276.
	HHR	Czuczman, M.S. et al., "Rituximab/CHOP chemoimmunotherapy in patients (PTS) with low grade lymphoma (LG/F NHL): progression free survival (PFS) after three years (median) follow-up." <i>Blood</i> , 1999, 94(1):99a, abstract 432.
	IIR	Davis, T.A. et al., "Retreatments with Rituxan (Rituximab, IDEC-C2B8) have significant efficacy, do not cause harm, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL)," <i>Blood</i> , 1997, 90(10):509A, abstract #2269.
	JJR	Davis, T.A. et al., "Therapy of B cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression," <i>Clinical Cancer Research</i> , 1999, 5(3):611-615.
	KKR	Davis, T. et al., "Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with Rituximab and alpha interferon: interim analysis," <i>Proceedings of the American Society of Clinical Oncology</i> , 1998 17: 11a, abstract #39.
	LLR	Davis, T. et al., "Rituximab: Phase II (PII) 1, 2, 5, retreatment (ReRx) study in patients (PTS) 15-17 with low-grade or follicular (LG/F) NHL," <i>Blood</i> , 1998, 92(10 Suppl 1): 414a, abstract #1710.
	MMR	Demidem, A. et al., "Chimeric anti-CD20 (IDE-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs," <i>Cancer Biotherapy & Radiopharmaceuticals</i> , 1997, 12(3):177-186.
	NNR	Dillman, R.O., "Antibodies as cytotoxic therapy," <i>Journal of Clinical Oncology</i> , 1994, 12(7):1497-1515.
	OOR	Flinn, I.W. et al., "In vivo purging and adjuvant immunotherapy with Rituximab during PBSC transplant for NHM," <i>Blood</i> , 1998, 92(10 Suppl 1):648a, abstract #2673.
	PPR	Greiner, J.W. et al., "Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo," <i>Science</i> , 1987, 235(4791):895-898.
	QQR	Grillo-López, A., "Treatment options for patients with relapsed low-grade or follicular lymphoma: The role of IDEC-C2B8," <i>Tenth International Conference on Monoclonal Antibody Immunoconjugates for Cancer</i> , March 9-11, 1995, 8:60, abstract #10.
	RRR	Grossbard, M., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80(4):863-878.
	SSR	Hagenbeek, A., et al., "Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma," for European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group, <i>Journal of Clinical Oncology</i> , 1998, 16(1):41-47.
	TTR	Horning, S.J. et al. "Rituximab treatment failures: tositumomab and iodine I-131 tositumomab [Bexxar®] can produce meaningful durable responses," <i>Blood</i> , 2002, 100(11):357a, abstract #1385.
	UUR	Janakiraman, N. et al., "Rituximab: correlation between effector cells and clinical activity in NHL," <i>Blood</i> , 1998, 92(10):337a, abstract #1384.
	VVR	Klarnet, J.P. et al., "Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory," <i>J Immunol</i> , 1987, 138(11):4012-4017.
	WWR	Knox, S.J. et al., "Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma," <i>Clinical Cancer Research, The American Association for Cancer Research</i> , 1996, 2(3):457-470.
	XXR	Kuzel, T. et al., "A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1," <i>Cancer Biotherapy</i> , 1993, 8(1):3-16.
	YYR	Lauria, F. et al., "Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation," <i>BMT</i> , 1996, 18(1):79-85.



YY	ZZR	Link, B., et al., "Phase I/II study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL," <i>Proceedings of the American Society of Clinical Oncology</i> , 1998, 17:3a, No. 7.
	AAAR	Lum, L.G. et al., "The kinetics of immune reconstitution after human marrow transplantation," <i>Blood</i> , 1987, 69(2):369-380.
	BBBBR	Maloney, D.G. et al., "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDE-C2B8) in patients with recurrent B-cell lymphoma," <i>Blood</i> , 1994, 84(8):2457-2466.
	CCCR	Maloney, D.G. et al., "IDE-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma," <i>J Clin Oncol</i> , 1997, 15(10):3266-3274.
	DDDR	McLaughlin, P. et al., "Efficacy controls and long-term follow-up of patients (PTS) treated with rituximab for relapsed or refractory, low-grade or follicular NHL," <i>Blood</i> , 1998, 92(10):414a-415a, abstract #1712.
	EEER	Murray, J. et al., "Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo," <i>Journal of Biological Response Modifiers</i> , 1990, 9(6):556-563.
	FFFR	Nakamura, K. et al., "Effect of alpha-interferon on anti-alpha-fetoprotein-monoclonal-antibody targeting of hepatoma," <i>Oncology</i> , 1993, 50(1):35-40.
	GGGR	O'Brien, S. et al., "Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy," <i>N Engl J Med</i> , 1994, 330(5): 319-322.
	HHHR	O'Brien., S. et al., "Phase I/II Study of Rituxan in chronic lymphocytic leukemia (CLL)," <i>Blood</i> , 1998, 92:105a, abstract #431.
	IIRR	Pietersz, G.A. et al., "The Use of monoclonal antibody conjugates for the diagnosis and treatment of cancer," <i>Immunol Cell Biol</i> , 1987, 65(pt 2):111-125.
	JJIR	Press, O. et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 1987, 69(2):584-591.
	KKKR	Press, O.W., et al., "Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates," <i>Cancer Journal from Scientific American, Scientific American, Inc</i> , 1998, 4(2):S19-S26.
	LLLR	Press, O., et al., "A phase I/II trial of high dose iodine-131-anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas," <i>Proc Annu Meet Am Soc Clin Oncol</i> , 1998, 17 A9.
	MMMR	Reff, M. et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> , 1994, 83(2):435-445.
	NNNR	Shipp et al. "The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma," <i>New England J Med</i> , 1993, 329(14):987-994.
	OOOR	Smalley, R. et al., "Interferon alpha combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma," <i>New England Journal of Medicine</i> , 1992, 327(19):1336-1341.
	PPPR	Soiffer, R.J. et al, "Clinical and immunologic effects of prolonged infusion of low- dose recombinant Interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation," <i>Blood</i> , 1992, 79(2):517-526.
	QQQR	Soiffer, R.J. et al., "Effect of low-dose Interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation," <i>Blood</i> , 1994, 84(3):964-971.
	RRRR	Solal-Célyny, P. et al., "Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial," <i>Journal of Clinical Oncology</i> , 1998, 16(7):2332-2338.
	SSSR	Tobinai, K. et al., "Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDE-C2B8, rituximab) in relapsed B-cell lymphoma," <i>Annals of Oncology</i> , 1998, 9(5):527-534.
	TTTR	Tsai, D. et al., "Progressive intermediate grade non-Hodgkin's lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCT) has a high response rate to Rituximab," <i>Blood</i> , 1998, 92(10):415a, abstract #1713.
	UUUR	Van der Kolk, L.E. et al., Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial," <i>Blood</i> , 1998, 92(10 Suppl 1):241b, abstract #4037.
	VVVR	Van der Kolk, L.E. et al., "Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B- cell lymphoma: A phase I/II clinical trial," <i>British Journal of Haematology</i> , 1998, 102(1):243 [Combined Haematology Congress of the International Society of Haematology and the European Hematology Association, Amsterdam, Netherlands, July 4-8, 1998].
	WWWR	Venugopal, P. et al., "Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by <i>in vitro</i> exposure to cytokines," <i>Blood</i> , 1998, 92(10):247a, abstract #1009.
↓	XXXR	Vey, N. et al., "A pilot study of autologous bone marrow transplantation followed by recombinant Interleukin-2 in malignant lymphomas," <i>Leukemia & Lymphoma</i> , 1996, 21(1-2):107-114.



Y	YYYR	Wadler S, et al., Principles of immunotherapy: Modulation of cytotoxic drugs by interferons," <i>Seminars in Oncology</i> , 1992, 19(2 suppl 3):45-48.
	ZZZR	Wahl, R.L. et al., "Successful re-treatment of non-Hodgkin's lymphoma (NHL) with iodine-131 anti-B1 antibody (Meeting abstract)," <i>Proc Annu Meet Am Soc Clin Oncol</i> , May 1998, 17:40a, abstract #156.
	AAAAR	Welte, K. et al, "Defective Interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified Interleukin 2," <i>Blood</i> , 1984, 64:380-5.
	BBBBR	Winkler, U., et al., Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody Rituximab," <i>Blood</i> , 1998, 92(10):285b, abstract #4228.
	CCCCR	Wiseman, O., et al., IDEC-Y2B8 radioimmunotherapy: Baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry. <i>Blood</i> , 1998, 92(10):417a, abstract #1721.
	DDDDR	Witherspoon, R.P. et al., "Immunologic reconstitution after human marrow grafting," <i>Semin Hematol</i> , 1984, 21(1):2-10.
	EEEEER	Witzig, T. et al., "IDEC-Y2B8 Radioimmunotherapy: Responses in patients with splenomegaly," <i>Blood</i> , 1998, 92(10):417(a), #1722.
	FFFFR	Witzig, T.E. et al., "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma," <i>J Clin Oncol</i> , 1999, 17(12): 3793-3803.
✓	GGGGR	Yokota, S. et al., "Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin," <i>Cancer Research</i> , 1990, 50:32-37.

Examiner	M. C. DAVIS	Date Considered:	08/04/04
----------	-------------	------------------	----------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 (modified)
(PW FORM PAT-1449)

Atty. Ref. No.
037003-0277847

Client Ref. No.
1998-30-0523VUS

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: GRILLO-LOPEZ

Appln. No.: 09/762,587

Filing Date: September 6, 2001

Date: April 26, 2004

Page 1 of 2

Examiner: M.T.B. Davis | Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
AR			
BR			
CR			

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
DR						
ER						
FR						

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

YLS	GR	Chinn PC, et al., "Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma," <i>Int J Oncol</i> , 1999, 15:1017-25.
	HR	Chinn PC, et al., "IDE-C-Y2B8: a 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium," <i>Proc Am Assoc Cancer Res</i> , 1999, 40:574 (Abstract #3786).
	IR	Davis TA, et al., "90Yttrium labeled anti-CD20 therapy for recurrent B-cell lymphoma," <i>Blood</i> , 1995, 86(10):273a (Abstract #1080).
	JR	Gordon LI, et al., "Zevalin™ (IDE-C-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL): interim results," <i>Blood</i> , 1999, 94(10):91a (Abstract #396).
	KR	Gordon LI, et al., "Update on IDE-C-YB8 (Zevalin™) radioimmunotherapy of B-cell NHL," <i>J Immunother</i> , 1999, 22(5) (Abstract #459).
	LR	Grillo-Lopez AT, et al., "Treatment (RX) of relapsed non-Hodgkin's lymphoma (NHL) using the 90-Yttrium (90Y) labeled anti-CD20 monoclonal antibody (MAB) IDE-C-Y2B8: a Phase I clinical trial (P1 CT)," <i>Ann Oncol</i> , 1996, 7(3 Suppl):57 (Abstract #195).
✓	MR	Grillo-Lopez AT, et al., "Phase I study of IDE-C-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma," <i>Blood</i> , 1995, 86(10):55a (Abstract #207).
	NR	Grillo-Lopez AT, et al., "Phase I and II studies in patients with non-Hodgkin's lymphoma," <i>Antibody Engineering</i> , 1994. <i>Page ? Reviewed but cannot be published.</i> YLS.
YLS	OR	Knox SJ, et al., "90Y-anti-CD20 monoclonal antibody therapy for recurrent B-cell lymphoma," <i>Int J Radiat Oncol Biol Phys</i> , 1995, 32:215.
	PR	Knox SJ, et al., "90Y-anti-CD20 monoclonal antibody therapy (IDE-C-Y2B8) for recurrent B-cell lymphoma," <i>J Immunother</i> , 1994, 16(2):161 (Abstract #51).
	QR	Marquez SD, et al., "Hematological toxicity in radioimmunotherapy is predicted both by the computer absorbed whole body dose (cGy) and by the administered dose (mCi)," <i>Int J Radiat Oncol Biol Phys</i> , 1997, 39:327 (Abstract #2173).
	RR	White CA, et al., "Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDE-C-Y2B8 Phase I/II 90yttrium trial," <i>Ann Oncol</i> , 1999, 10(3 Suppl):64 (Abstract #215).
✓	SR	White CA, et al., "Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma," <i>Eur J Cancer</i> , 1999, 35:S57 (Abstract #107).

APR 26 2004
U.S. PATENT & TRADEMARK OFFICE

<i>[Signature]</i>	TR	White CA, et al., "Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 9 anti-idiotype monoclonal antibodies," <i>Blood</i> , 1996, 87(9):3640-9.
	UR	Wiseman GA, et al., "Zevalin biodistribution and dosimetry estimated normal organ absorbed radiation doses are not affected by prior therapy with rituximab," <i>Blood</i> , 1999, 94(10):92a (Abstract #403).
	VR	Wiseman GA, et al., "Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than to normal organs," <i>Proc Am Soc Clin Oncol</i> , 1999, 18(1 Suppl):4a (Abstract #13).
	WR	Wiseman GA, et al., "IDECA-Y2B8 (90Yttrium ibritumomab tiuxetan) radioimmunotherapy safety results in relapsed or chemotherapy refractory non-Hodgkin's lymphoma (NHL) patients treated at reduced doses because of pre-existing thrombocytopenia," <i>Int J Radiat Oncol Biol Phys</i> , 1999, 45(3 Suppl):390 (Abstract #2217).
	XR	Wiseman GA, et al., "Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody," <i>Clin Cancer Res</i> , 1999, 5(Suppl):3281S-3286S.
	YR	Wiseman GA, et al., "Final dosimetry results of IDEC-Y2B8 Phase I/II 90Yttrium radioimmunotherapy trial in non-Hodgkin's lymphoma (NHL)," <i>J Nucl Med</i> , 1999, 40(10 Suppl):64P, (Abstract #260).
	ZR	Wiseman GA, et al., "90Yttrium labeled IDEC-Y2B8 anti-CD20 radioimmunotherapy of non-Hodgkin's lymphoma," <i>Cancer Biother Radiopharm</i> , 1999, 14(4):315 (Abstract #2).
	AAR	Wiseman GA, et al., "Non-Hodgkin's lymphoma tumor and bone marrow radiation doses from radioimmunotherapy with IDECA-Y2B8 yttrium-90 anti-CD20 monoclonal antibody," <i>J Nucl Med</i> , 1998, 39(5):69P (Abstract #267).
	BBR	Wiseman GA, et al., "Whole-body gamma camera image quantification from multiple camera types for radioisotope therapy dosimetry," <i>J Nucl Med</i> , 1998, 39(5 Suppl):185P (Abstract #836).
	CCR	Wiseman GA, et al., "IDECA-Y2B8 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim analysis," <i>Cancer Biother Radiopharm</i> , 1998, 13(4):317 (Abstract #51).
	DDR	Wiseman GA, et al., "Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90Yttrium Radioimmunotherapy," <i>Proc Am Soc Clin</i> , 1998, (Abstract).
	EER	Wiseman GA, et al., "Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8," <i>Int J Radiat Oncol Biol Phys</i> , 1998, 42(1 Suppl):130 (Abstract #11).
	FFR	Wiseman GA, et al., "Radioimmunotherapy relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90 Yttrium anti-CD20 monoclonal," <i>Cancer Biother Radiopharm</i> , 1998, 13(1):59 (Abstract #22).
	GGR	Wiseman GA, et al., "IDECA-Y2B8 (90Y conjugated anti-CD20) dosimetry calculated from 111In anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM)," <i>Blood</i> , 1997, 90(10):510a (Abstract #2273).
	HHR	Wiseman GA, et al., "Y-90 anti-CD20 monoclonal antibody (IDECA-Y2B8) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma, <i>J Nucl Med</i> , 1997, 38(5 Suppl):251 (Abstract #1062).
	IIR	Witzig TE, et al., "Prospective randomized controlled study of Zevalin™ (IDECA-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results," <i>Blood</i> , 1999, 94(10):631a (Abstract #2805).
	JJR	Witzig TE, et al., "Reduced-dose Zevalin™ radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: report of interim results of a Phase II trial," <i>Blood</i> , 1999, 94(10):92a (Abstract #400).
	KKR	Witzig TE, et al., "Commonly used response criteria for non-Hodgkin's lymphoma (NHL) applied to IDECA-Y2B8 radioimmunotherapy trial: importance of "normal" lymph node size," <i>Proc Am Soc Clin Oncol</i> , 1999, 18:41a (Abstract #152).
	LLR	Witzig TE, et al., "IDECA-Y2B8 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma," <i>J Immunother</i> , 1998, 21(6):463.
<i>[Signature]</i>	MMR	Witzig TE, et al., "IDECA-Y2B8 90Yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a Phase I/II trial," <i>Blood</i> , 1997, 90(10):586a (Abstract #2606).

Examiner	M. C. DAVIS	Date Considered:	04/04/04
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449 (modified)
(PW FORM PAT-1449)

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: May 26, 2004

Page 1 of 1

Atty. Ref. No. 037003-0277847	Client Ref. No. 1998-30-0523VUS
Applicant: GRILLO-LOPEZ	
Appln. No.: 09/762,587	
Filing Date: September 6, 2001	
Examiner: M.T.B. Davis	Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
AR			
BR			
CR			
DR			
ER			
FR			
GR			
HR			

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
IR						
JR						
KR						
LR						
MR						
NR						
OR						
PR						

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

TS	QR	Idec Pharmaceuticals v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
↓	RR	Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
	SR	
	TR	
	UR	
	VR	
	WR	
	XR	
	YR	
	ZR	

Examiner M.T. DAVIS Date Considered: 08/04/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.